- Home
- SDGR vs XERS Comparison
SDGR vs XERS Comparison
Compare SDGR & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDGR
- XERS
- Stock Information
- Founded
- SDGR 1990
- XERS 2005
- Country
- SDGR United States
- XERS United States
- Employees
- SDGR N/A
- XERS N/A
- Industry
- SDGR Biotechnology: Pharmaceutical Preparations
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- SDGR Health Care
- XERS Health Care
- Exchange
- SDGR Nasdaq
- XERS Nasdaq
- Market Cap
- SDGR 1.4B
- XERS 1.3B
- IPO Year
- SDGR 2020
- XERS 2018
- Fundamental
- Price
- SDGR $20.87
- XERS $9.57
- Analyst Decision
- SDGR Buy
- XERS Strong Buy
- Analyst Count
- SDGR 8
- XERS 7
- Target Price
- SDGR $26.75
- XERS $8.00
- AVG Volume (30 Days)
- SDGR 1.3M
- XERS 2.3M
- Earning Date
- SDGR 11-05-2025
- XERS 11-06-2025
- Dividend Yield
- SDGR N/A
- XERS N/A
- EPS Growth
- SDGR N/A
- XERS N/A
- EPS
- SDGR N/A
- XERS N/A
- Revenue
- SDGR $237,917,000.00
- XERS $246,025,000.00
- Revenue This Year
- SDGR $22.73
- XERS $43.89
- Revenue Next Year
- SDGR $19.85
- XERS $20.40
- P/E Ratio
- SDGR N/A
- XERS N/A
- Revenue Growth
- SDGR 18.59
- XERS 35.62
- 52 Week Low
- SDGR $16.60
- XERS $2.82
- 52 Week High
- SDGR $28.47
- XERS $10.03
- Technical
- Relative Strength Index (RSI)
- SDGR 50.88
- XERS 68.59
- Support Level
- SDGR $19.99
- XERS $9.11
- Resistance Level
- SDGR $23.02
- XERS $10.03
- Average True Range (ATR)
- SDGR 1.12
- XERS 0.40
- MACD
- SDGR 0.03
- XERS 0.04
- Stochastic Oscillator
- SDGR 47.94
- XERS 79.78
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).